基因泰克Vixarelimab在中国获批临床，治疗溃疡性结肠炎

Investment Ratings - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors [1] - The biotechnology sector is rated as Neutral [1] - Other pharmaceutical sectors are also rated as Neutral [1] Core Insights - The report maintains a positive outlook on the pharmaceutical industry, expecting returns to exceed the CSI 300 Index by more than 5% over the next six months [2][7] - The approval of Genentech's Vixarelimab for clinical trials in China for the treatment of ulcerative colitis is a significant development [5][7] - The pharmaceutical sector experienced a decline of 1.57% on May 23, 2024, underperforming the CSI 300 Index by 0.41 percentage points [4] Summary by Sections Market Performance - On May 23, 2024, the pharmaceutical sector's performance was -1.57%, ranking 12th among 31 sub-industries [4] - Offline pharmacies (+0.18%) and medical devices (+0.07%) showed positive performance, while hospitals (-2.84%) and other biopharmaceuticals (-2.61%) lagged [4] Industry News - The approval of Vixarelimab by the National Medical Products Administration (NMPA) is noteworthy, as it is a potential "first-in-class" drug [5] - Other companies, such as Ganli Pharmaceutical and Jiuzhou Pharmaceutical, received various drug approvals, indicating ongoing activity in the sector [6] Company News - Ganli Pharmaceutical received approval for its insulin injection in Mexico, expanding its market reach [6] - Jiuzhou Pharmaceutical's approval for lacosamide, a third-generation anti-epileptic drug, highlights advancements in treatment options [6] - Huazhong Shuanghe and Puli Pharmaceutical also reported successful drug registrations, showcasing a trend of regulatory approvals in the industry [6]